Isohelix, a UK-based specialist biological sample collection company, has begun the process to gain full regulatory approval of the GeneFix Saliva DNA Collectors from the US Food and Drug Administration (FDA).
The GeneFix Saliva DNA/RNA Collection devices are designed for the collection and preservation of DNA/RNA from saliva, providing patients with the opportunity to provide high-quality samples for molecular diagnostics at both point of care settings and for over the counter direct to consumer genetic testing (OTC).
Isohelix has submitted via the FDA’s Pre-Submission process, which allows the company to clarify its testing and validation approach, confirm the appropriate regulatory application pathway (510k) and gain additional procedural feedback from the FDA with the aim of making the final submission process more efficient.
Since 2013, Isohelix has been successfully supplying its range of high-quality DNA and RNA saliva collectors and isolation products to the diagnostics, clinical and research markets, with many products already certified for use as IVDs across the globe. Isohelix is an international business marketing its sizeable product range through customers in many countries worldwide.
Tom Hole, CEO of Isohelix, said: "The US is a particularly attractive territory and the 510 (K) would allow us to supply our products into the rapidly expanding areas of Molecular and Precision Genetic Diagnosis and Testing, where saliva has become a strong choice as an alternative to blood or the use of buccal swabs. Isohelix provides saliva collectors that are proven to cope with the most demanding downstream processes, yet are easy to use for automated applications, non-hazardous and reliably stabilise both DNA and RNA over extended periods at room temperature.
For further details please visit www.isohelix.com.
